Abstract
The production of antibody-drug conjugates (ADCs) has been in great demand in the field of cancer therapeutics. Although cysteine-based conjugation is the most common and well known process for producing ADCs, multiple analytical methods are required for accurate drug-antibody ratio (DAR) determination due to the heterogeneity of the ADCs. Here we report various analytical methods for DAR analysis of traditional cysteine-based ADCs; additionally, apply a good manufacturing practice (GMP) strategy to produce a four hundred milligram ADC batch for use in good laboratory practice (GLP) studies. The work described herein not only evaluates several analytical performances but also provides guidance for future phase appropriate ADC production while establishing a unique analytical strategy.
Similar content being viewed by others
References
M. Abdollahpour-Alitappeh, M. Lotfinia, T. Gharibi, J. Mardaneh, B. Farhadihosseinabadi, P. Larki, B. Faghfourian, K. S. Sepehr, K. Abbaszadeh-Goudarzi, G. Abbaszadeh-Goudarzi, B. Johari, M. R. Zali, and N. Bagheri, J. Cell Physiol., 2019, 234, 5628.
J. M. Lambert and A. Berkenblit, Annu. Rev. Med., 2018, 69, 191.
R. Lyon, Drug Discov. Today Technol., 2018, 30, 105.
A. Beck, V. D’Atri, A. Ehkirch, S. Fekete, O. Hernandez-Alba, R. Gahoual, E. Leize-Wagner, Y. Francois, D. Guillarme, and S. Cianférani, Expert. Rev. Proteomics., 2019, 16, 337.
K. Todoroki, T. Yamada, H. Mizuno, and T. Toyo’oka, Anal. Sci., 2018, 34, 397.
US Food and Drug Administration (FDA), Guidance for Industry—Monoclonal Antibodies Used as Reagents in Drug Manufacturing, https://www.fda.gov/media/72408/download.
US Food and Drug Administration (FDA), Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products—Guidance for Industry, https://www.fda.gov/media/77796/download.
Y. Matsuda, V. Robles, M-C. Malinao, S. James, and B. A. Mendelsohn, Anal. Chem., 2019, 91, 12724.
F. Debaene, A. Boeuf, E. Wagner-Rousset, O. Colas, D. Ayoub, N. Corvaïa, A. Van Dorsselaer, A. Beck, and S. Cianférani, Anal. Chem., 2014, 86, 10674.
L. N. Le, J. M. R. Moore, J. Ouyang, X. Chen, M. D. H. Nguyen, and W. J. Galush, Anal. Chem., 2012, 84, 7479.
D. Firth, L. Bell, M. Squires, S. Estdale, and C. McKee, Anal. Biochem., 2015, 485, 34.
M. Källsten, R. Hartmann, K. Artemenko, S. B. Lind, F. Lehmann, and B. Bergquist, Analyst, 2018, 143, 5487.
Y. Matsuda, C. Clancy, Z. Tawfiq, V. Robles, and B. A. Mendelsohn, ACS Omega, 2019, 4, 20564.
P. D. Senter and E. L. Sievers, Nat. Biotechnol., 2012, 30, 631.
H. Tilly, F. Morschhauser, N. L. Bartlett, A. Mehta, G. Salles, C. Haioun, J. Munoz, A. I. Chen, K. Kolibaba, D. Lu, M. Yan, E. Penuel, J. Hirata, C. Lee, and J. P. Sharman, Lancet Oncol., 2019, 20, 998.
Z. Tawfiq, N. C. Caiazza, S. Kambourakis, Y. Matsuda, B. Griffin, J. C. Lippmeier, and B. A. Mendelsohn, ACS Omega, 2020, 5, 7193.
K. Yamada, N. Shikida, K. Shimbo, Y. Ito, Z. Khedri, Y. Matsuda, and B. A. Mendelsohn, Angew. Chem., Int. Ed., 2019, 58, 5592.
Y. Matsuda, K. Yamada, T. Okuzumi, and B. A. Mendelsohn, Org. Process Res. Dev., 2019, 23, 2647.
S. O. Doronina, B. E. Toki, M. Y. Torgov, B. A. Mendelsohn, C. G. Cerveny, D. F. Chace, R. L. DeBlanc, R. P. Gearing, T. D. Bovee, C. B. Siegall, J. A. Francisco, A. F. Wahl, D. L. Meyer, and P. D. Senter, Nat. Biotechnol., 2003, 21, 778.
G. T. Hermanson, “Bioconjugate Techniques”, 3rd ed., 2013, Elsevier, London, 240–246.
S. Fekete, J.-L. Veuthey, A. Beck, and D. Guillarme, J. Pharm. Biomed. Anal., 2016, 130, 3.
V. D’Atri, R. Pell, A. Clarke, D. Guillarme, and S. Fekete, J. Chromatogr. A, 2019, 1586, 149.
Title 21 CFR Part 58 Good Laboratory Practice for Nonclinical Laboratory Studies, 18 February 2004.
B. Stump and J. Steinmann, Methods Mol. Biol., 2013, 1045, 235.
D. E. Shafer, J. K. Inman, and A. Lees, Anal. Biochem., 2000, 282, 161.
J. C. Han and G. Y. Han, Anal. Biochem., 1994, 220, 5.
Y. Matsuda, M. C. Malinao, V. Robles, J. Song, K. Yamada, and B. A. Mendelsohn, J. Chromatogr. B, 2020, 1140, 121981.
S. Sakamoto and I. Hamachi, Anal. Sci., 2019, 35, 5.
K. Tsuchikama and A. An, Protein & Cell, 2018, 9, 33.
K. Maruyama and M. Kanai, Chem. Lett., 2019, 48, 1421.
C. L. Becker, R. J. Duffy, J. Gandarilla, and S. M. Richter, Methods Mol. Biol., 2019, 2078, 237.
Y. Zhang, S. Zhou, X. Chang, and X. Tao, Anal. Sci., 2019, 35, 1291.
M. K. Sharma, P. Dhakne, S. NN, P. A. Reddy, and P. Sengupta, Anal Sci., 2019, 35, 1069.
Y. Matsuda, M. Leung, T. Okuzumi, and B. A. Mendelsohn, Antibodies, 2020, 9, 16.
Acknowledgments
The authors wish to thank our colleagues from Ajinomoto Bio-Pharma Services, Inc., as follows: Mr. Shawn Littrell and Mr. William Wittbold for technical assistance for GLP study; Dr. Wen Chen and Mr. Keenan Moi for technical assistance with the ADC analysis; Mr. David Correa, Mr. Steve Folio, Mr. Darwin Richardson, Mr. Bert Barbosa, and Dr. Tatsuya Okuzumi from Ajinomoto Co., Inc. for many helpful discussions and suggestions in this study.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Tawfiq, Z., Matsuda, Y., Alfonso, M.J. et al. Analytical Comparison of Antibody-drug Conjugates Based on Good Manufacturing Practice Strategies. ANAL. SCI. 36, 871–875 (2020). https://doi.org/10.2116/analsci.19P465
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2116/analsci.19P465